Merck, CRT in deal for PRMT5 inhibitors
Merck & Co. Inc. (NYSE:MRK) partnered with Cancer Research Technology Ltd. to develop inhibitors of protein arginine methyltransferase 5, which the companies said have potential to treat cancer and non-cancer blood disorders.
The inhibitors were developed by Australian cooperative research center Cancer Therapeutics CRC Pty Ltd. (CTx) (Melbourne, Australia), with...